GenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017
The work will be presented in a poster session at the NAACR Conference in Washington DC on Tuesday, April 4, 2017 from 8:00AM - Noon in the poster area in Halls A-C of the Convention Center. It is Section 15, Poster #30, Abstract #3369 which is part of the Epigenetics 3 Section of the Molecular and Cellular Biology & Genetics Session. The project is titled, "Epigenetic DNA Methylation Profiling of Triple Negative Breast Cancer: A Quantitative NGS Approach".
The lead author on the study who will be presenting it is Dr. Kimberly Arnold from Department of Medical Sciences at the University of Delaware and the Center of Transnational Cancer Research at the Helen F. Graham Cancer Center in Newark, Delaware. The poster, which describes the under-served need for a prognostic marker in triple negative breast cancer, the approach used by GenPro in discovering the novel epigenetic marker (EpiMarker), new molecular insights into genes and pathways that were illuminated by GenPro, and plans to verify and translate the new EpiMaker into a fast, low-cost, high-throughput qPCR assay are discussed. The poster can be viewed at: NAACR 2017 Poster